Cancer: Drugs

Dr. Gibson
To ask the Secretary of State for Health when the National Institute for Health and Clinical Excellence will produce its guidance on the use of (a) bevacizumab, (b) sorafenib, (c) sunitinib (second-line) and (d) temsirolimus for the treatment of advanced and metastatic renal cell carcinoma in the NHS.

Dawn Primarolo
The National Institute for Health and Clinical Excellence currently expects to issue final guidance to the national health service on bevacizumab, sorafenib and temsirolimus for the first line treatment and sorafenib and sunitinib for the second-line treatment of advanced and/or metastatic renal cell carcinoma in June 2009.